SAREPTA THERAPEUTICS INC

NASDAQ: SRPT (Sarepta Therapeutics, Inc.)

Kemas kini terakhir: 2 hari lalu, 11:48AM

36.18

-1.13 (-3.03%)

  • 1H -3.03%
  • 5H -15.88%
  • 1B -0.69%
  • 6B -71.46%
  • Tahun Ke Tarikh -70.84%
  • 1T -69.03%
  • 5T -77.42%
Penutupan Terdahulu 37.31
Buka 37.05
Jumlah Dagangan 3,231,837
Purata Dagangan (3B) 3,899,928
Modal Pasaran 3,555,661,824
Harga / Pendapatan (P/E Ke hadapan) 25.97
Harga / Jualan (P/S) 1.93
Harga / Buku (P/B) 3.42
Julat 52 Minggu
34.10 (-5%) — 173.25 (378%)
Tarikh Pendapatan 5 Aug 2025 - 11 Aug 2025
Margin Keuntungan -11.12%
Margin Operasi (TTM) -40.33%
EPS Cair (TTM) -2.64
Pertumbuhan Hasil Suku Tahunan (YOY) 80.20%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 248.40%
Jumlah Hutang/Ekuiti (D/E MRQ) 118.73%
Nisbah Semasa (MRQ) 4.02
Aliran Tunai Operasi (OCF TTM) -547.15 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -741.26 M
Pulangan Atas Aset (ROA TTM) -2.19%
Pulangan Atas Ekuiti (ROE TTM) -23.61%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menurun Menurun
Biotechnology (Global) Menurun Menurun
Stok Sarepta Therapeutics, Inc. Menurun Menurun

AISkor Stockmoo

0.3
Konsensus Penganalisis 1.0
Aktiviti Orang Dalam NA
Volatiliti Harga 3.0
Purata Bergerak Teknikal -1.0
Osilator Teknikal -2.0
Purata 0.25

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
SRPT 4 B - - 3.42
EXEL 12 B - 19.42 5.49
BPMC 8 B - - 24.15
BBIO 8 B - - -
MDGL 6 B - - 8.69
TGTX 6 B - 147.28 25.64

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 4.44%
% Dimiliki oleh Institusi 90.38%
204.30204.30173.40173.40142.50142.50111.60111.6080.7080.70Harga Sasaran MedianQ4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
34.10 (-5%) — 173.25 (378%)
Julat Harga Sasaran
40.00 (10%) — 125.00 (245%)
Tinggi 125.00 (Needham, 245.50%) Beli
Median 98.00 (170.87%)
Rendah 40.00 (HC Wainwright & Co., 10.56%) Pegang
Purata 90.08 (148.98%)
Jumlah 10 Beli, 3 Pegang
Harga Purata @ Panggilan 40.93
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Scotiabank 06 Jun 2025 80.00 (121.12%) Beli 43.01
20 Mar 2025 80.00 (121.12%) Pegang 73.45
HC Wainwright & Co. 22 May 2025 40.00 (10.56%) Pegang 38.79
07 May 2025 40.00 (10.56%) Pegang 36.72
JP Morgan 20 May 2025 84.00 (132.17%) Beli 39.99
Wells Fargo 08 May 2025 100.00 (176.40%) Beli 36.52
11 Apr 2025 115.00 (217.86%) Beli 51.03
Cantor Fitzgerald 07 May 2025 81.00 (123.88%) Beli 36.72
19 Mar 2025 163.00 (350.53%) Beli 79.97
Goldman Sachs 07 May 2025 100.00 (176.40%) Beli 36.72
Guggenheim 07 May 2025 98.00 (170.87%) Beli 36.72
Morgan Stanley 07 May 2025 113.00 (212.33%) Beli 36.72
11 Apr 2025 182.00 (403.04%) Beli 51.03
Needham 07 May 2025 125.00 (245.49%) Beli 36.72
03 Apr 2025 183.00 (405.80%) Beli 58.61
Oppenheimer 07 May 2025 123.00 (239.97%) Beli 36.72
Piper Sandler 07 May 2025 70.00 (93.48%) Beli 36.72
21 Apr 2025 110.00 (204.04%) Beli 55.23
RBC Capital 07 May 2025 58.00 (60.31%) Pegang 36.72
31 Mar 2025 87.00 (140.46%) Pegang 63.82
Deutsche Bank 19 Mar 2025 99.00 (173.63%) Pegang 79.97
Papar semua

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
15 Jun 2025 Pengumuman Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
04 Jun 2025 Pengumuman U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4
21 May 2025 Pengumuman Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
16 May 2025 Pengumuman Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
16 May 2025 Pengumuman Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2
13 May 2025 Pengumuman Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
08 May 2025 Pengumuman Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
06 May 2025 Pengumuman Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments
22 Apr 2025 Pengumuman Sarepta Therapeutics to Announce First Quarter 2025 Financial Results
15 Apr 2025 Pengumuman Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs
04 Apr 2025 Pengumuman Sarepta Therapeutics Provides Update on ELEVIDYS
31 Mar 2025 Pengumuman Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Papar semua
44.7444.7441.4841.4838.2238.2234.9634.9631.7031.70Jun 4Jun 4Jun 5Jun 5Jun 6Jun 6Jun 9Jun 9Jun 10Jun 10Jun 11Jun 11Jun 12Jun 12Jun 13Jun 13

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.0000.000-2.000-2.000-4.000-4.000-6.000-6.000-8.000-8.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda